Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.31 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3089379 | 0.85 | SSTR4 (0.33) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL3068316 | 0.81 | SLC22A12 (0.33) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL3087081 | 0.78 | ALDH1A1 (0.38) | LMNAMAPT | |
| SCHEMBL3362479 | 0.77 | SLC22A12 (0.36) | SLC22A12 | |
| SCHEMBL3079212 | 0.68 | ALDH1A1 (0.48) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL3091847 | 0.68 | IDO1 (0.41) | LMNAMAPTL3MBTL1 | |
| SCHEMBL3360367 | 0.68 | KDM4E (0.33) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL3209179 | 0.68 | KDM6B (0.32) | SLC22A12 | |
| SCHEMBL6244422 | 0.67 | PPARG (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL3081181 | 0.67 | SLC22A12 (0.32) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445476-B2 | Carbacephem β-lactam antibiotics | ACHAOGEN, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20100267686-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| EP-2205600-A1 | CARBACEPHEM ß -LACTAM ANTIBIOTICS | Achaogen, Inc. (US) | 2010-07-14 | — | — | EP | disclosed |
| WO-2010030811-A2 | CARBACEPHEM β-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| WO-2009055696-A1 | CARBACEPHEM β-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267686-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | MGAM, MGAM2, B2M | CHRM2 49/4885CHRM4 605/4885CHRM5 1549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.